Gracell: Speeding up CAR T cells

Gracell's manufacturing platform could accelerate production of CAR T cell therapies from two weeks to one day

With a platform that could reduce the manufacturing time of autologous CAR T cells from two weeks to one day, Gracell is lining up a set of therapies it could produce with the method.

Gracell Biotechnologies Co. Ltd. founder, Chairman and CEO William Cao told BioCentury that the company, which emerged from stealth in February with a $85 million series B round led by Temasek, plans to address the lengthy production times and high costs of CAR T cell therapies.

Conventional CAR T cell manufacturing -- which involves genetic modification of

Read the full 899 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE